Title: Gene Therapy - Coming of Age
Speaker: Yatish Lad, Vice President, Head of Early Development
Abstract/speaker bio: Oxford Biomedica is a leading, fully integrated, cell and gene therapy group. They have built a sector-leading lentiviral vector delivery system, LentiVector® platform, which is leveraged to develop in vivo and ex vivo products both in-house and with partners. They have also created a valuable proprietary portfolio of cell and gene therapy product candidates in the areas of oncology, ophthalmology, CNS disorders and liver diseases. They have a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people.
For further information on BridgeBio visit: https://www.oxb.com/
The Industry Insight Seminars provide a great opportunity to:
- Increase awareness of commercial translation
- Form connections between academics and industry
- Network with potential collaborators
These seminars are suitable for all scientists with some knowledge or interest in each topic area, from PhD students to PIs along with biotech, SMEs and Pharma companies.